Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.69 |
| ▸ | MEN1 | O00255 | 5/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.69 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.68 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.63 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.63 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.63 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.63 |
| ▸ | TP53 | P04637 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 7/20 | 0.62 |
| ▸ | RAB9A | P51151 | 7/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | JAK2 | O60674 | 1/20 | 0.59 |
| ▸ | TYK2 | P29597 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30416797 | 0.98 | KMT2A (0.67) | KMT2AMEN1KDM4EL3MBTL1GRM4 | |
| SCHEMBL14324709 | 0.87 | GRM4 (0.72) | KMT2AMEN1KDM4EL3MBTL1GRM4 | |
| SCHEMBL3770882 | 0.85 | KCNK3 (0.66) | KMT2AMEN1GRM4ALDH1A1JAK2 | |
| SCHEMBL30417156 | 0.82 | SORT1 (0.71) | KMT2AMEN1KDM4EL3MBTL1CHRNB2 | |
| SCHEMBL20610060 | 0.82 | SORT1 (0.71) | KMT2AMEN1KDM4EL3MBTL1CHRNB2 | |
| SCHEMBL8616448 | 0.82 | TP53 (0.65) | KMT2AMEN1KDM4EL3MBTL1CHRNB2 | |
| SCHEMBL18146062 | 0.82 | SMN1; SMN2 (0.64) | KMT2AMEN1KDM4EL3MBTL1CHRNB2 | |
| SCHEMBL20632155 | 0.82 | SMN1; SMN2 (0.64) | KMT2AMEN1KDM4EL3MBTL1CHRNB2 | |
| SCHEMBL17675194 | 0.81 | MEN1 (0.71) | KMT2AMEN1KDM4EL3MBTL1CHRNB2 | |
| SCHEMBL8433498 | 0.81 | MEN1 (1.00) | KMT2AMEN1KDM4EL3MBTL1CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11919868-B2 | Heterocyclic compounds and related methods | RECURSION PHARMACEUTICALS, INC. (US) | 2024-03-05 | — | — | US | claimed |
| EP-4006035-B1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | NEUPHARMA INC (US) | 2023-11-22 | — | — | EP | claimed |
| CN-110869350-B | Alkynyl compounds, their preparation and their therapeutic use | 赛诺菲 | 2023-05-02 | — | — | CN | claimed |
| CN-110869350-B | Alkynyl compounds, their preparation and their therapeutic use | 赛诺菲 | 2023-05-02 | — | — | CN | disclosed |
| CN-109053558-B | Synthesis method of N-heterocyclic amide derivative | 贵州大学 | 2022-02-18 | — | — | CN | disclosed |
| EP-1014962-A4 | ANTITHROMBOTIC AGENTS | LILLY CO ELI (US) | 2007-06-27 | — | — | EP | disclosed |
| EP-1014962-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 2000-07-05 | — | — | EP | disclosed |
| WO-1999000121-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 1999-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11919868-B2 | Heterocyclic compounds and related methods | CYP11B2, CYP11B1, MAPT | KMT2A 4355/4885MEN1 473/4885KDM4E 4633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.